Deep vein thrombosis and pulmonary embolism in the Chinese population by Chan, J et al.
Title Deep vein thrombosis and pulmonary embolism in the Chinesepopulation
Author(s) Nandi, PL; Li, WS; Leung, R; Chan, J; Chan, HT
Citation Hong Kong Medical Journal, 1998, v. 4 n. 3, p. 305-310
Issued Date 1998
URL http://hdl.handle.net/10722/45395
Rights Creative Commons: Attribution 3.0 Hong Kong License
HKMJ Vol 4 No 3 September 1998      305
Deep vein thrombosis
Introduction
In 1934, Homans1 described the relationship between
deep vein thrombosis (DVT) and pulmonary embolism
(PE). Since then, thromboembolism has been well
recognised as a major public health problem in the
West. A study performed in the United Kingdom
found that 0.9% of all patients admitted to hospital
had fatal pulmonary embolism.2 The prevalence of
DVT in surgical patients is 10% to 80%, depending
on the type of surgery and individual patient risk
factors.3,4 It is generally accepted that postoperative
DVT is rare in Asians, particularly in the Chinese
population.
Prevalence of deep vein thrombosis
There have been several recent reports about DVT
and PE in the Chinese population in recent years;
they cite a prevalence of DVT of 2.6% to 17%.5-10
A similar figure has been reported for Malaysian
and Thai patients.11,12 In an autopsy study, Chan
and Hoaglund8 reported a prevalence of pulmonary
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thromboembolism (PTE) of 0.75% in the adult Hong
Kong Chinese population. A similar retrospective
study by Chau et al9 reported a prevalence of 2.1%.
Recent data from a study performed in Hong Kong
between 1990 and 1994 show an increased prevalence
of PTE—namely, 4.7%.13 These figures are within
the lower range of the prevalence of PTE in Caucasian
patients—reported rates of significant PTE from
all autopsies are 3.4% to 9.0% in the United States14
and 12.8% in the United Kingdom.15 Interestingly,
there seems to be a seasonal variation in the fre-
quency of PTE in Hong Kong (as diagnosed during
necropsy), and two troughs can be identified: one in
early summer (June and July) and the other in early
winter (November and December). The prevalence of
pulmonary thromboembolism varies from 1.6% to
5.5%.16 Seasonal variations have also been found in
patients in Birmingham, United Kingdom—namely,
the presence of two peaks in spring and autumn. It
has been noted that the humidity, which is low in
winter in Hong Kong, is similar to that of summer
in the United Kingdom16; however, its association
with PTE is unclear.
The site of DVT also differs in Caucasian and
Chinese patients. In the latter, the thrombi are mostly
found in the calf veins5,7,17 whereas in Caucasians,
proximal veins are more commonly involved. The
probability of PTE complicating DVT has been
reported to be 46%, 67%, and 77% for the calf, thigh,
and pelvic veins, respectively.13
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Prevalence of venous thrombosis in Chinese
patients
The explanation for the low prevalence of DVT in the
Chinese population is a matter of speculation. Several
factors are likely to be responsible; they include race,
diet, and climate. Racial factors alone are unlikely to
be the explanation. Chinese people who have been
living in western countries for several generations
may have a much higher incidence of DVT. This is
also the case for African Americans, whose prevalence
of DVT is similar to white Americans.18 Fibrinolytic
activity in the blood is higher in Africans, Indians, and
New Guineans than it is in Caucasians.19,20 Studies in
rats show that fibrinolytic activity can be reduced by
a raised plasma lipid level which, in turn, is influenced
by the dietary intake of fat.21 A low dietary fat intake
is a possible explanation for the low incidence of
DVT in the Chinese population. Lawrence at al22 have
demonstrated a seasonal variation in the incidence of
DVT: many more cases of DVT occur in the six cold
months of the year than during the warmer months.
The tropical climate of south-east Asia may thus be
partly responsible for a low prevalence of DVT in Asians.
Risk factors for the development of deep vein
thrombosis
Extensive epidemiological studies of patients with
thromboembolism have identified several factors that
enhance the risk of the development of DVT. These
factors include surgery, age, sex, heart failure, history of
previous thromboembolism, direct trauma to the leg,
use of oral contraceptives, and limb weakness. Patients
who are admitted to hospital can be classified into three
groups according to their degree of risk, as recommended
by the European Consensus Group (Box).23
The prevalence of DVT associated with surgical
procedures that last more than 4 hours can be as high
as 80%; it is also high in patients undergoing surgery
for malignant disease. The prevalence in Caucasians
varies for different types of operation, as follows:
neurosurgery, 29% to 50%; general surgery, 30%;
urological surgery, 50%; and orthopaedic surgery,
54%.24 The reported figures for Chinese patients are
as follows: neurosurgery, 10%; general surgery, 8.5%;
colorectal surgery, 4%9; and orthopaedic surgery,
53.3%.17 Surgery causes changes in coagulation and
platelet function that may favour thrombus formation.
Immobility during surgery causes stasis in the venous
sinuses of the calf veins and pressure against the
operating table can lead to vessel wall hypoxia. These
factors fulfill Virchow’s triad of stasis, vessel wall
injury, and altered coagulation that initiates thrombus.
An increased incidence of DVT with increasing age,
especially in patients aged more than 60 years has been
noted in both autopsy and clinical studies. Venous
thrombosis is more common in women than in men.
This difference is most pronounced during the repro-
ductive age, when there is a two- to three-fold increase.
The rate of fatal PE in Chinese women is significantly
higher than in Chinese men.13 The primary site of
thrombi in Caucasian patients is the thigh. In Chinese
patients, however, the majority of thrombi are limited
to the calf veins, and there is a 40% to 53% risk of
thrombosis in an injured leg and 25% to 52% in a non-
injured leg.13,17
Women who use oral contraceptives show a four-
fold increase in the incidence of thromboembolism.
There is also evidence that contraceptive pills are
associated with an increased risk of postoperative
thromboembolism when they are taken in the month
prior to surgery.25 Tso et al6 have reported a 10.5%
incidence of DVT in Chinese women who were taking
oral contraceptives prior to pelvic surgery.
Limb weakness is a well-known risk factor. In a
study of patients who had recently had a stroke, Warlow
et al26 reported an incidence of DVT of 60% in the
paralysed leg compared to only 7% in the non paralysed
leg in both Caucasian and Chinese patients. An inci-
dence of 17% of DVT in the paralysed limb has been
reported in Chinese patients.7
Diagnosis of deep venous thrombosis
Some objective diagnostic tests, preferably non-invasive,
are needed to screen patients who have a high risk of
DVT developing or who have signs and symptoms of
Classification of patients according to the degree
of risk
Low-risk patients
<40 years without additional risk factors
Minor surgery (<30 minutes)
Moderate-risk patients
>40 years
Major surgery (>30 minutes)
Oral contraceptives
Immobilised medical patients with active disease
High-risk patients
Previous deep vein thrombosis or pulmonary
embolism
Major surgery for malignant disease
Orthopaedic surgery on lower limbs
Stroke, heart failure, or acute myocardial infarction
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DVT. It is important that clinicians maintain a high
level of awareness of the risk so that early diagnosis can
be made and treatment initiated to prevent the serious,
often fatal complications of PE. Treatment for DVT
should not be given without objective confirmation of
the diagnosis. Only about 30% of the patients with
clinically diagnosed DVT also have the diagnosis
confirmed by reliable objective tests.27
Venography
The traditional ‘gold standard’ method used to diagnose
DVT has been venography. Ultrasonic imaging has
now replaced venography as the new diagnostic
standard in many hospitals. All of these tests, how-
ever, have limitations as screening tests. Venography
is invasive, needs to be done in the X-ray department,
and cannot be repeated readily. In addition, asympto-
matic thrombi tend to be small, non-occlusive, and
limited to the calf; they are thus difficult to detect by
using non-invasive tests.
Although morbidity can be associated with veno-
graphy, there is none associated with ultrasonography,
which can be used as an alternative to venography in
most patients. Furthermore, even the morbidity from
venography is much less than the morbidity associated
with anticoagulation therapy.
Non-invasive tests
Non-invasive tests can be performed at the bedside
and can be repeated. Real-time B-mode compression
ultrasonography is sensitive and specific for
diagnosing proximal vein thrombosis and is more
accurate than impedance plethysmography. Doppler
ultrasonography is a sensitive method for detecting
proximal vein thrombosis, but it is less sensitive for
the diagnosis of calf vein thrombosis. Impedance
plethysmography is both sensitive and specific for
diagnosing completely occluded proximal veins, but
it is insensitive for diagnosing thrombosed proximal
veins that are partially occluded. Leg scanning that
uses fibrinogen I 125 has been primarily used as a
screening test for medical and surgical patients who
have a high risk of DVT developing. It is also used as
an adjunct to impedance plethysmography to confirm
or exclude the diagnosis of clinically suspected venous
thrombosis. Leg scanning that uses fibrinogen I 125
accurately diagnoses DVT, but there is some concern
about the possible transmission of blood-borne
diseases.
Other techniques used to diagnose venous throm-
bosis include isotopic methods, blood tests, and other
non-invasive tests. However, these tests have not been
evaluated fully and their role in clinical practice
remains unproven.27 Radioisotopic techniques include
radionuclide venography with technetium Tc 99m–
labelled macro-aggregated albumin or human albumin
microspheres, technetium Tc 99m–labelled red blood
cells, and indium 111–labelled platelets. The limited
accuracy of the various isotopic techniques reported
in the literature to date, their invasiveness, the radiation
exposure, and the high cost of preparing the isotopes
argue against their use for the diagnosis of venous
thrombosis.
Blood tests can detect the presence of intravascular
fibrin by measuring fibrinopeptide A in the plasma or
fibrin/fibrinogen degradation products in the serum
such as D-dimer and fragment E. These tests have been
shown to be sensitive but not specific, and their use is
primarily confined to research centres.27 Other non-
invasive tests like phleborrheography, thermography,
and strain-gauge plethysmography require further
evaluation.
Advances in prophylaxis of venous thrombosis
Prophylaxis of venous thrombosis in Caucasian
patients is cost-effective and reduces fatal compli-
cations and treatment requirements. Selective pro-
phylaxis in Chinese patients undergoing high-risk
surgery should be considered. The physical methods
of prophylaxis described below can be safely used
for these patients. If one decides to rely on pharma-
cological methods, however, low molecular weight
heparins should be used where possible, as they are
effective and safe.
There are several different effective methods
available for preventing venous thrombosis and these
can be divided into physical and pharmacological
methods.
Physical methods
The use of graduated compression stockings is the
most popular physical method used to prevent DVT.
Intermittent compression devices are more cumber-
some to use and less well tolerated by patients. A new
method has been introduced recently—that is, the
arterial-venous impulse foot pump. The pump is
applied to the patient’s foot and provides compression
to the plantar venous plexus. Its use has significantly
reduced the incidence of DVT.28 One advantage is
good patient tolerability compared with conventional
intermittent pneumatic compression devices, which
enables its use after an operation until the patient is
ambulant.
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Pharmacological methods
Low-dose heparin is the mainstay of pharmaco-
logical prophylaxis. Prophylaxis with low-dose heparin
(5000 U, every 8 or 12 hours) reduces the prevalence
of DVT by 66% and that of PE by 50%.3  Other drugs
that have varying degrees of success include warfarin,
aspirin, and dextran. However, recent interest in heparin
prophylaxis has centred on low molecular weight
heparins. These are as effective as unfractionated
heparin. Because of the longer half-life of low molecular
weight heparins, only a once-daily dosage is needed,
which is more convenient for patients and nurses. There
is also less bruising at injection sites.
Prolonged prophylaxis
Standard prophylaxis for venous thrombosis usually
lasts for 1 to 2 weeks after operation. Some patients
develop DVT after discharge from hospital and late
death from PE is not uncommon after surgery.29 In
recent years, there has been discussion as to whether
there is an indication to continue prophylaxis for more
than 1 to 2 weeks. There have been several prospective
double-blind trials in which low molecular weight
heparins were given to patients undergoing hip surgery
(ie a 1-month course that started preoperatively and
that continued postoperatively). The studies show
that prolonged prophylaxis significantly reduced veno-
graphically detected DVT approximately 1 month
postoperatively.30
Orgaran (danaparoid sodium; Durbin, Middlesex,
UK) is a new low molecular weight heparinoid that
consists of a mixture of heparin sulphate, dermatan
sulphate, and chondroitin sulphate; it is chemically
distinct from heparin. Although not in widespread use,
several studies of patients who had a high risk of
developing DVT have shown the drug to be effective
and comparable to low-dose heparin.31
Treatment of venous thrombosis
The aims of treating patients with venous thrombosis
are to prevent death from pulmonary embolism, to
reduce morbidity from the acute episode, and to
minimise postphlebitic syndrome.
Preventing death from pulmonary embolism
The following four treatment approaches can be used
to prevent death from pulmonary embolism:
Anticoagulant therapy
There is good evidence that anticoagulants are effect-
ive in reducing mortality from PE. With adequate
heparinization, symptomatic PE occurs in only 5% of
patients with DVT, and fatal PE in less than 0.5%.32 If
the diagnosis of DVT has been confirmed in a Chinese
patient, giving anticoagulants ought to be seriously
considered, especially if there are thrombi in the
femoropopliteal or ileofemoral veins. These thrombi
are prone to becoming dislodged and may cause
fatal PE. Anticoagulation is directed at controlling
the thrombotic process that has already been initiated.
Intravenously injected heparin is the most effect-
ive treatment: the preferred method is continuous
administration, starting with a loading dose of 5000
to 10 000 U and varying the dose depending on the
activated partial thromboplastin time, which should
be kept within the therapeutic range (1.5 to 2 times the
control). The two advantages of this approach are to
achieve a more uniform level of anticoagulation and a
lower incidence of bleeding complications.
The duration of heparin therapy depends on the
extent of venous thrombosis. For femoropopliteal or
ileofemoral venous thrombosis with or without PE,
heparin treatment should be continued for 10 to 14
days—even longer if the patient remains at risk. A
course of oral anticoagulants should be started while
the patient is still receiving heparin treatment, and
should be discontinued only when a satisfactory level
of anticoagulation has been achieved. The maintenance
dose must be monitored carefully to keep the activated
partial thromboplastin time approximately between 1.5
to 2 times the control. Chinese patients usually require
a lower dose of anticoagulants than do Caucasian
patients (unpublished observations).
The duration of the course of oral anticoagulants
depends on the severity of thrombosis. For isolated
calf vein thrombosis, treatment lasting 4 to 6 weeks
is sufficient. However, to treat femoropopliteal or
ileofemoral vein thrombosis with or without PE,
anticoagulant therapy should be continued for 3 to 6
months.
Vena caval interruption
Vena caval interruption should be considered when
anticoagulant treatment is contra-indicated or if it has
failed.
Thrombolytic therapy
Thrombolytic therapy is more effective than heparin
in preventing death in patients who have massive
PE and are in shock, or in those with underlying heart
or lung disease in whom even a small or moderate
embolus may be life-threatening. Thrombolytic agents
usually used are streptokinase, urokinase, or tissue
plasminogen activator.
HKMJ Vol 4 No 3 September 1998      309
Deep vein thrombosis
Surgical embolectomy
Urgent pulmonary embolectomy is usually restricted
to patients with a saddle embolus that is lodged in the
main pulmonary artery, or in patients with massive PE
whose blood pressure cannot be maintained despite
thrombolytic therapy.
Minimising postphlebitic symptoms
In 60% to 70% of patients with proximal vein throm-
bosis and 30% to 40% of those with calf vein throm-
bosis, postphlebitic syndrome can develop even after
full treatment with anticoagulants. The frequency and
severity of postphlebitic symptoms are lower in patients
whose venous thrombosis is treated early with throm-
bolytic agents. The severity of postphlebitic symptoms
can be minimised by about 50% when compression
stockings are used soon after venous thrombosis is
diagnosed.33
Conclusion
Venous thrombosis is a major public health problem
in western countries. It would appear that the incidence
of venous thrombosis and PE is rising in Chinese
patients. Ultrasonic imaging has now replaced veno-
graphy as the new diagnostic standard in many
hospitals. Prophylaxis against venous thrombosis
reduces the incidence of thrombosis by 66% and that
of PE by 50%, and prophylaxis should be considered
for Chinese patients who have a high risk of developing
postoperative DVT. Treatment of venous throm-
bosis should not be undertaken without objective
confirmation of the diagnosis.
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